Skip to content
★ Sign in to follow
Shandong Wohua Pharmaceutical Co., Ltd. logo

Shandong Wohua Pharmaceutical Co., Ltd. Stock: price and insider trades · China

沃华医药

CN·Mcap CN¥3.7BHealth Care

Shandong Wohua Pharmaceutical Co., Ltd.: what insiders have been doing

This page follows insider dealings at Shandong Wohua Pharmaceutical Co., Ltd. as filed with SSE / SZSE (CSRC), a company from the Health Care sector. In the past year (7 November 2025 to 7 November 2026), 3 filings came from 1 insider.

The flow runs one way only: 3 sales worth €591k, from 1 insider, and no purchase. One trade stands out by size: a sale of €237k from 张戈, disclosed on 8 June 2026.

With 3 filings in twelve months, the company is more active than the median of 2 filings across the 522 companies we follow on the same exchange. Since 2021, the database holds no purchases and 5 sales by insiders of the company.

Publication is fast: at least half of the trades appear on SSE / SZSE (CSRC) on the same day. Until a filing is published, the market cannot know about the trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.

In the same sector, recent insider purchases at Dynavox Group AB and Vetoquinol SA also feature in our signals. Every figure here comes from the filings published by SSE / SZSE (CSRC) and describes the past, not future prices; it is not investment advice.

Insider Decl.
5
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€650,114
5 ops. · all time

Who traded when

BuySale
张戈3 sales

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 7,296 of 26,912 companies
63.0
score / 100
Value
39
Quality
87
FCF yld3.5%
Earn yld2.6%
EV/EBITDA27.4x
ROE19%
Gross mgn75%
Net mgn12%
Debt/EBITDA0.0x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥6.36
Analyst consensus
·
Income statement
RevenueCN¥817M
Gross profitCN¥615.8M75% margin
EBITDACN¥133.9M16% margin
Net incomeCN¥95.7M15.9% margin
Valuation
PER (trailing)28.9x
P/Book5.5x
Beta0.32
Balance sheet & cash
Market capCN¥3.7B
Total debtCN¥1.2M
Free Cash FlowCN¥127.7M
Debt / Equity0%
Profitability & ownership
ROE18.6%
ROA8.6%
% insiders54.0%
% institutions1.1%
Last declaration on 11 June 2026
Declarations5 total
  • ▼
    董事,董事会秘书Executives
    1M CNY10SZSE
    235,524 shares@ CN¥46.230429.9% of flowA股XSHESZSE:273000000712975550
  • ▼
    董事,董秘Executives
    1M CNY10SZSE
    235,500 shares@ CN¥46.194329.9% of flowA股XSHESZSE:273000000713118500
  • ▼
    董事,董秘Executives
    2M CNY11SZSE
    297,300 shares@ CN¥48.590240.2% of flowA股XSHESZSE:273000000698048960
  • ▼
    董事Executives
    152,400 CNY10SZSE
    20,000 shares33.3% of flowA股XSHESZSE:173000004442553600
  • ▼
    董事Executives
    308,800 CNY14SZSE
    40,000 shares66.7% of flowA股XSHESZSE:173000004420840220

5 of 5 declarations

About Shandong Wohua Pharmaceutical Co., Ltd.

沃华医药 is a company specializing in the healthcare and pharmaceutical sector. It is listed on the XSHE market.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations